|
Medicinska genetika
Povezave
25 priporočil EU
Medgen
Medicinska genetika,
družba za zdravstvene
dejavnosti d.o.o.
Ulica Bratov Babnik 10,
1000 Ljubljana
Tel.: 01 510 71 30
Fax: 01 510 71 31
GSM: 051 429 723
Email: info@medgen.si
Ambulanta
za klinično genetiko Ljubljana
Ulica Bratov Babnik 10
1000 Ljubljana
Naročanje: 01 510 71 30
Ambulanta
za klinično genetiko Postojna
Prečna 2
6230 Postojna
Naročanje: 01 510 71 30
ali GSM 041 40 63 63
|
www.gendia.net
Diagnostic tests for genetic diseases can be divided into cytogenetics,
molecular cytogenetics (FISH) and molecular genetics.
Whereas cytogenetic and molecular cytogenetic tests are widely
available, molecular tests for many genetic diseases are not
available in many countries.
Several decades of intensive research on the molecular causes
of human genetic diseases have resulted in a large list of molecular
tests that can be offered to diagnose genetic diseases. In many
countries molecular laboratories have been established that offer
these tests to patients and their families.
Unfortunately, there are huge differences with respect to accessibility,
price and quality of the molecular diagnostic testing in the various
countries. The spectrum of genetic diseases that can be tested
varies from several hundreds in countries with a well-developed
service system to only a few in most countries of the world.
One of the main problems is the relative rareness of most genetic
diseases, resulting in a small number of requests per disease per
laboratory. This impairs a cost-effective and reliable service.
A second problem is the large number of genetic diseases that can
be tested for by DNA technology (now over 2000). Since most
laboratories offer less than 50 molecular tests, usually for the
same diseases, the majority of genetic disorders cannot be diagnosed
locally or even nationally. For these rare diseases it can be quite
difficult to find a laboratory willing to do the test. Even when
a laboratory is found, the turn around time and financial requirements
usually are uncertain. Furthermore, it is difficult to check whether
minimal quality requirements are met as quality trials are not
offered for this category of diseases and there are no platforms
where referring clinicians can discuss their positive and negative
experiences. In
summary, the accessibility, cost-effectiveness and quality of
diagnostic tests for rare genetic disorders could be substantially
improved, which is the main goal of the GENDIA Network.
www.gendia.net
|